EraCal Therapeutics Ltd. is an emerging biotechnology firm that originated from the University of Zurich and Harvard University. The business is privately owned by a group of investors with expertise in biotechnology, including BERNINA BioInvest, Redalpine, and UZH Life Sciences Fund. EraCal Therapeutics Ltd., a preclinical biotechnology company, was established as a spin-off from the University of Zurich and Harvard University, and focuses on developing innovative drugs to address various ailments.